Jia Yueting’s FF responded: There will be no risk of delisting when submitting financial reports in a timely manner, and the expected losses in the third quarter will increase
Interest income drives Q3 net profit to return to growth, and the "big and comprehensive" Lizhu Group increases profits but does not increase revenue | Read financial reports
The company's senior executives resigned collectively, and after the actual controller was arrested for bribery, Hongda New Materials rose instead of falling
Liankang Biotechnology Group (00690.HK): Bogutai? (Terripatide injection) application for marketing has been officially accepted by the State Food and Drug Administration